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A novel expression system based on engineered variants of the yeast (Saccharomyces cerevisiae) dsRNA virus L-A was
developed allowing the in vivo assembly of chimeric virus-like particles (VLPs) as a unique platform for a wide range of
applications. We show that polypeptides fused to the viral capsid protein Gag self-assemble into isometric VLP chimeras
carrying their cargo inside the capsid, thereby not only effectively preventing proteolytic degradation in the host cell cytosol,
but also allowing the expression of a per se cytotoxic protein. Carboxyterminal extension of Gag by T cell epitopes from human
cytomegalovirus pp65 resulted in the formation of hybrid VLPs that strongly activated antigen-specific CD8
+ memory T cells ex
vivo. Besides being a carrier for polypeptides inducing antigen-specific immune responses in vivo, VLP chimeras were also
shown to be effective in the expression and purification of (i) a heterologous model protein (GFP), (ii) a per se toxic protein
(K28 a-subunit), and (iii) a particle-associated and fully recyclable biotechnologically relevant enzyme (esterase A). Thus, yeast
viral Gag represents a unique platform for the in vivo assembly of chimeric VLPs, equally attractive and useful in vaccine
development and recombinant protein production.
Citation: Powilleit F, Breinig T, Schmitt MJ (2007) Exploiting the Yeast L-A Viral Capsid for the In Vivo Assembly of Chimeric VLPs as Platform in Vaccine
Development and Foreign Protein Expression. PLoS ONE 2(5): e415. doi:10.1371/journal.pone.0000415
INTRODUCTION
Viral expression systems can be classified into three types based on
the regulatory and/or structural viral component that drives
protein expression: (i) plasmid-based vectors containing promoter
elements from either pro- or eukaryotic viruses; (ii) infectious viral
vectors in which the gene of interest is integrated into the viral
genome and expressed from a viral promoter in an appropriate
host; (iii) virus-like particles (VLPs), also called pseudovirions,
representing subunit structures composed of multiple copies of
a viral capsid and/or envelope protein capable to self-assemble into
VLPs of defined spherical symmetry in vivo [1–3]. Currently, VLPs
composed of a structural protein are often used as particulate
antigen in the design of prototype vaccines as they possess several
advantages over conventional monomeric protein immunogens
[4]. Firstly, most VLPs can be produced in large quantity in
a heterologous host. Secondly, due to their particle structure and
high molecular weight, VLPs can be easily purified in a preparative
scale. Thirdly, a number of particle forming proteins tolerate
insertion of foreign amino acid sequences without affecting in vivo
self-assembly competence. Such chimeric or hybrid VLPs,
exploited as platform for the display of antigenic determinants in
a polyvalent manner, have already been shown to be promising
candidates in the development of various subunit vaccines [5].
Here, a novel expression system based on the non-infectious
yeast (S. cerevisiae) dsRNA virus L-A was designed. This mycovirus
represents an autonomously replicating, encapsidated dsRNA
element that stably persists in the cytoplasm of an infected yeast
cell without conferring a recognizable phenotype upon its host [6].
As member of the Totiviridae family, L-A contains a linear non-
segmented dsRNA genome (4.6 kb) comprising two overlapping
ORFs, gag and pol. While gag encodes the major capsid protein Gag
(76 kDa), pol specifies a multifunctional RDRP which is in vivo
expressed as a 171 kDa Gag/Pol fusion protein by a [21]
ribosomal frame-shift event [6,7]. As Gag has been shown to be
sufficient to drive in vivo self-assembly into VLPs, Pol is dispensable
for viral coat assembly [8]. However, N-acetylation of Gag
(catalyzed by Mak3p of the host cell) is an essential prerequisite
for VLP formation in vivo [9]. The 40 nm L-A capsid has a 120-
subunit structure composed of 118 Gag proteins and two copies of
Gag/Pol configured as an icosahedron of triangulation class T=1
[7,10–12]. In the present study, we used Gag - and specifically
designed variants thereof - for the in vivo assembly of VLP chimeras
suitable for heterologous protein production and display of
vaccine-relevant immunogens.
RESULTS
Chimeric Gag assembles into yeast VLPs
Since in the natural L-A virus, Pol (as C-terminal part of Gag/Pol)
extends into the interior of the capsid to ensure replication and
transcription of the viral genome [11], we replaced Pol by
a truncated version of the immunodominant phosphoprotein pp65
from human cytomegalovirus (HCMV) to modify the inner surface
of the capsid. The truncated protein (Dpp65) comprised the C-
terminal amino acids 358-561 of pp65 flanked by the CD8
+ T-cell
epitopes AE44 and AE45 [13] at its N- and C-terminus,
respectively. The resulting Gag/Dpp65 protein fusion (101 kDa)
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PLoS ONE | www.plosone.org 1 May 2007 | Issue 5 | e415as well as non-modified (naked) Dpp65 (24.9 kDa) were separately
expressed in yeast and analyzed for expression level and protein
stability. In the Gag/Dpp65 protein fusion, Dpp65 is fused in the
[0]-frame to the 39-end of gag resulting in a protein fusion that is
ought to self-assemble (via its Gag domain) into VLPs encapsulat-
ing Dpp65 as C-terminal cargo (Figure 1A). Western analysis of
cell extracts from yeast expressing either naked Dpp65 or Gag/
Dpp65 revealed only a weak signal for non-fused Dpp65 in
contrast to an intense signal seen in cells expressing Gag/Dpp65
(Figure 1B). The observed instability of the naturally short-lived
Dpp65 protein in the multiple protease-deficient mutant strain
S86c could not even be prevented in mutant hosts defective in
components of the ubiquitin-proteasome-system (UPS) nor in
a yeast Dpep4 mutant devoid of vacuolar proteases (data not
shown). Interestingly however, Dpp65 was significantly stabilized
and effectively protected from proteolytic degradation when
expressed in a particulate manner as C-terminal protein fusion
to Gag (Figure 1B). The competence of Gag/Dpp65 for in vivo self-
assembly into hybrid VLPs was demonstrated by analyzing its
sedimentation profile during sucrose gradient centrifugation and
by electron microscopy of gradient-purified VLPs: Gag/Dpp65
formed isometric particles which showed a similar sedimentation
behaviour as natural L-A virions (Figure 2A and 2B).
Gag/Dpp65 activates HCMV-specific CD8
+ memory
T-cells ex vivo
Antigenicity of recombinant Gag/Dpp65 particles was determined
in an ex vivo stimulation assay allowing quantification of HCMV-
specific memory T cell responses in human whole blood by FACS
analysis [14,15]. For such an assay, both VLPs (Gag and Gag/
Dpp65) were expressed and assembled in yeast and partially
purified by centrifugation through a sucrose cushion (Figure 3A).
T cell stimulation assays performed on whole blood of a HCMV
seropositive donor indicated that pp65-specific CD4
+ and CD8
+
T-lymphocytes were strongly activated to maximal frequencies of
2.64% and 0.22% by HCMV positive control antigens, while no
immune response was seen in the negative control. Interestingly,
cushion-purified Gag/Dpp65 as well as non-modified Gag only
poorly activated CD4
+ cells (,0.1%, Figure 3B), while chimeric
Gag/Dpp65 particles induced a pronounced CD8
+ T-cell response
in a dose-dependent manner that was even higher than in the
positive control (0.35% versus 0.22%; Figure 3C). In contrast to
Gag/Dpp65, unmodified Gagdidnot significantly activate HCMV-
specific CD8
+ cells, not even at the highest concentration tested
(Figure 3C). To demonstrate that the observed CD8
+ T cell
response was caused by the Dpp65 moiety of the chimeric particles,
recombinant VLPs were isolated from yeast, purified by sucrose
gradient centrifugation and subsequently analyzed by SDS-PAGE
and Coomassie-Blue staining. As shown in Figure 4A, gradient-
purified VLPs only contained two protein species representing Gag
and Gag/Dpp65, thereby demonstrating that both preparations
were of high purity (.95%). For T cell stimulation, whole blood of
HCMV-seropositive donors was supplemented with 5 mg gradient-
purified VLPs; a lysate from HCMV-infected fibroblasts served as
positive control, a HCMV-seronegative blood sample as negative
control to demonstrate antigen specificity of the immune response.
As expected, no T cell response was detectable in the negative
control, while a significant CD4
+ T lymphocyte response was seen
in seropositive samples against the positive control antigen
(Figure 4B and 4C). In contrast to unmodified Gag, chimeric
Gag/Dpp65-VLPs caused a significant activation of CD4
+ T cells
only in donor 2 (Figure 4B). As shown before for cushion-purified
particles, gradient-purified Gag/Dpp65 showed significantly elevat-
ed frequencies of activated CD8
+ T cells that were up to 25-fold
increased over unmodified Gag (Figure 4C). Qualitatively the same
result was obtained by analyzing chimeric VLPs in which the
antigenic Dpp65 moiety was expressed on the outer VLP surface by
in-frame insertion into surface-exposed loops of Gag immediately
upstream of amino acid position S182 and flanked by flexible
spacers (Powilleit and Schmitt, unpublished). These data demon-
strate that Gag/Dpp65 expressed and assembled into yeast VLPs
exposing Dpp65 either inside the particle or at the outer VLP
surface, both possess antigenic properties (in particular to activate
CD8
+ memory T cells) that are due to their HCMV-specific Dpp65
moiety. To further investigate the potential of Gag/Dpp65 particles
as unique yeast vaccine, we are currently analyzing native Gag/
Dpp65 particles in a murine HCMV model of HLA transgenic mice
for the induction of a protecting in vivo immune response. That
antigens exposed inside chimeric yeast VLPs are indeed efficiently
processed by immune cells in vivo resulting in a humoral immune
response was demonstrated by using native Gag/K28a VLPs
(assembled in and isolated from a GTXa expressing yeast strain)
which induced K28a-specific antibodies in rabbit (Figure 5A and
Figure 1. Expression of a Gag/Dpp65 fusion protein in yeast. (A) Schematic outline of Gag/Dpp65 before and after in vivo assembly into chimeric
yeast VLPs. (B) SDS-PAGE and anti-pp65 immunoblot of crude extracts from yeast expressing either Dpp65 (lane 1), Gag (lane 2), or Gag/Dpp65 (lane
3). To ensure in vivo translation initiation of N-terminally truncated Dpp65 (24.9 kDa), a methionine residue was added to the N-terminus of Dpp65
[M, prestained PAGE Ruler, Fermentas].
doi:10.1371/journal.pone.0000415.g001
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viral a/b toxin K28 is known to be toxic (in particular when
expressed in the ER lumen [16]), successful expression of Gag/
K28a particles demonstrates that chimeric Gag-VLPs are also
suitable for the expression of a per se lethal protein.
Chimeric VLPs as platform for protein expression
and purification
In contrast to monomeric protein fusions, hybrid VLPs are of high
molecular weight and can be easily prepared from crude cell
extracts by ultracentrifugation [4]. In this context, we exploited
Gag as particle-forming carrier to express and purify the green
fluorescent protein GFP as model polypeptide. For this purpose,
a Gag variant was constructed encoding a 105 kDa protein fusion
containing Gag at its N-terminus (to ensure in vivo VLP assembly
and GFP encapsulation), followed by an 11 amino acid T7 epitope
tag (for immunological detection) and a factor Xa cleavage site to
release mature GFP from Gag (Figure 6A). Yeast transformants
expressing such a construct (GTXG) were used for VLP
preparation, and western analysis of sucrose gradient fractions
revealed that GTXG (105 kDa) assembled into VLPs that showed
Figure 2. Sedimentation profile and electron microscopy of Gag/Dpp65 expressed in yeast demonstrate in vivo assembly into isometric VLP
chimeras. (A) Western analysis of chimeric Gag/Dpp65 particles and natural L-A virions assembled in yeast and purified by ultracentrifugation
through a linear sucrose gradient. Aliquots of each gradient fraction were separated by SDS-PAGE and probed with monoclonal anti-pp65 and
polyclonal anti-Gag, respectively [GP, gradient pellet; M, full range rainbow marker, Amersham]. (B) Electron micrograph of sucrose-gradient-purified
Gag/Dpp65 after negative staining with uranyl acetate/methyl cellulose [magnification 150,000; arrows indicate Gag/Dpp65 particles].
doi:10.1371/journal.pone.0000415.g002
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PLoS ONE | www.plosone.org 3 May 2007 | Issue 5 | e415Figure 3. Gag/Dpp65 expressed in yeast assembles into VLP chimeras strongly activating CD8
+ memory T cells in human whole blood. (A)
Western blot of Gag/Dpp65 (lane 1) and Gag (lane 2) expressed in yeast and partially purified as sucrose cushion pellet after ultracentrifugation.
Aliquots (20 ml each) of the indicated VLP preparation were subjected to SDS-PAGE followed by Coomassie-Blue staining and western analysis probed
with anti-Gag and/or anti-pp65 [M, full range rainbow marker, Amersham]. (B) Frequencies of antigen-specific CD4 and (C) CD8 T cell activation after
stimulation by sucrose cushion-purified yeast Gag and Gag/Dpp65 particles. Activated T cells were identified as CD69/IFN-c double-positive
lymphocytes by flow cytometry. Antigen samples were added to whole blood from HCMV seropositive donor 1. A VLP-free sample containing PBSE
buffer was included as negative control (NC), a lysate from HCMV-infected fibroblasts served as positive control (PC). The threshold of significant T cell
responses (0.05% of counted lymphocytes [15]) is indicated as dashed line.
doi:10.1371/journal.pone.0000415.g003
Yeast VLP Carrier System
PLoS ONE | www.plosone.org 4 May 2007 | Issue 5 | e415Figure 4. Purified Gag/Dpp65 chimeras induce an extensive human CD8 T cell response. (A) SDS-PAGE and anti-pp65 immunoblot of sucrose
gradient purified Gag and Gag/Dpp65 particles expressed and assembled in yeast [Coomassie-Blue staining and BSA (2.7 mg) were used for semi-
quantitative signal detection; M, full range rainbow marker, Amersham]. (B and C) Whole blood cells from three HCMV seropositive donors were
stimulated by the addition of either Gag or Gag/Dpp65 (5 mg each), and specifically activated CD4 (B) and CD8 (C) T cells were quantified as CD69/
IFN-c double-positive lymphocytes by flow cytometry. A lysate from HCMV-infected fibroblasts served as positive control (PC), whereas a lysate from
noninfected fibroblasts, a VLP-free buffer sample as well as blood cells from HCMV seronegative donor 5 were used as negative controls (NC). The
threshold of significant T cell responses (0.05% of counted lymphocytes [15]) is indicated as dashed line.
doi:10.1371/journal.pone.0000415.g004
Yeast VLP Carrier System
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(Figure 6B). To check whether the protein fusion is accessible to
factor Xa cleavage and subsequent release of its GFP moiety,
GTXG-VLPs (288 mg protein/ml) were treated with Triton X-
100, thereafter incubated with factor Xa and subsequently
subjected to SDS-PAGE and western analysis. As shown in
Figure 6C, detergent-treated GTXG-VLPs were efficiently
processed by factor Xa, liberating two protein moieties from the
GTXG precursor (both absent in negative controls) whose
calculated molecular weights are consistent with the presence of
monomeric (26.8 kDa) and dimeric (53.6 kDa) GFP. In direct
support, dimeric GFP was only seen in non-reducing SDS-PAGE
and completely disappeared under reducing conditions in the
presence of b-mercaptoethanol (data not shown). To investigate
the efficiency of preparative GFP purification, detergent-treated
GTXG particles (274 mg) were incubated in the presence of factor
Xa, VLP debris was removed by high-spin centrifugation
(100.0006g) and the resulting supernatant was treated with
Xarrest agarose to eliminate residual endoproteinase. Soluble
GFP released from the VLPs was precipitated by the addition of
ammonium sulfate, and the resulting pellet and supernatant
fraction was subsequently analyzed by SDS-PAGE probed with
anti-GFP and anti-T7. By this procedure, monomeric GFP
(26.8 kDa) and the larger GTX cleavage fragment (77.8 kDa)
were successfully released from the 105 kDa GTXG precursor
(Figure 6D). Furthermore, GFP could be purified in a single step
by hydrophobic interaction chromatography (HIC) as judged by
SDS-PAGE and western analysis (Figure 6D). GFP containing
fractions from the HIC column were 100-fold concentrated by
Amicon ultrafiltration, and the pooled HIC fractions as well as
filtrate and retentate after ultrafiltration were analyzed by SDS-
PAGE and Coomassie-Blue staining. As expected, GFP concen-
tration in the retentate was higher than in the pooled HIC
fractions or in the filtrate (Figure 6E). Moreover, the preparation
was highly pure, only showing two GFP-specific signals on non-
reducing SDS gels, a major 26.8 kDa protein representing
monomeric GFP and a minor 53.6 kDa species representing
dimeric GFP (Figure 6E). Based on the signal intensity after
Coomassie-Blue staining, the overall yield of GTXG-derived GFP
after sucrose gradient centrifugation and HIC purification was in
the range of 0.2 mg purified protein from 1 liter yeast culture (and
a density of 5610
8 cells/ml).
VLP chimeras as recyclable biocatalyst
To demonstrate the flexibility of the viral carrier for the expression
of a biotechnologically relevant enzyme, the GFP moiety in
GTXG was replaced by the carboxylesterase EstA from
Burkholderia gladioli [17], the resulting Gag/EstA protein fusion
was expressed in yeast and electron microscopy of sucrose
gradient-purified Gag/EstA particles confirmed in vivo assembly
into recombinant VLPs (Figure 7A). To demonstrate esterase
activity in the VLP chimeras, gradient-purified Gag/EstA particles
were analyzed in an enzyme activity assay using 4-nitrophenyla-
cetate as substrate. Since EstA is located inside the particle, the
substrate must pass the capsid pores to be converted into acetate
and 4-nitrophenol. Under the assay conditions used, the release of
4-nitrophenol was monitored through its absorption at 405 nm
that was shown to be linearly correlated to a concentration of up to
1 mM (regression coefficient=0.9974; Figure 7B). Based on these
parameters, gradient-purified Gag/EstA (70 ng and 280 ng) and
non-modified Gag (560 ng) were subsequently analyzed for
esterase activity; a VLP-free sample served as negative control to
detect autohydrolysis and unspecific breakdown of the ester
substrate. In contrast to unmodified VLPs, Gag/EstA chimeras
catalyzed the release of 4-nitrophenol and under steady state
conditions (reaching reaction equilibrium within 48 min), 67.9%
of the initial substrate were enzymatically converted into 4-
nitrophenol (Figure 7C).
Gag/EstA particles allow multiple substrate
conversions
To investigate whether particle-associated esterase can be recycled
and reused in multiple rounds of substrate conversion, gradient-
purified Gag/EstA particles (22.5 mg) were used in an enzyme
reaction (5 ml), isolated by ultracentrifugation, subsequently sub-
jected to SDS-PAGE and western analysis, and compared to the
same VLP charge prior to substrate conversion. Based on the
esterase signal intensity obtained after SDS-PAGE and Coomassie-
Blue staining, approximately one-third of the original particle
preparation had been recovered in the pellet fraction after a single
ultracentrifugation step (Figure 7D). Since Gag/EstA particles were
significantly diluted prior to ultracentrifugation, esterase protein
remaining in the final supernatant was not detectable in immuno-
blots. Most interestingly however, catalytic activity of Gag/EstA-
VLPs after recovery was not negatively affected and rather
resembled EstA activity in the original non-recycled VLPs. Using
an equal volume of Gag/EstA particles before and after recycling,
absolute esterase activity was three-fold lower in recycled VLPs;
however, given that one-third of the initial VLP amount (750 ng)
had been recycled, specific esterase activity in the Gag/EstA
chimeras before and after recycling was almost identical (Figure 7E),
demonstrating that VLP-associated EstA can be recycled and
repeatedly used in multiple rounds of enzyme-catalyzed substrate
conversion. Most interestingly however, the remarkable efficacy of
the VLP-associated enzyme becomes evident when specific esterase
activity of Gag/EstA particles (20.8 U mg
21 protein) is compared to
that after EstA cell surface expression in either yeast (S. cerevisiae)o r
bacteria (E. coli): in both cases, esterase activity was significantly
lower and ranged from 1.3 to 2.7 U mg
21 protein in yeast [18] and
0.001 to 0.023 U mg
21 protein in bacteria [19].
DISCUSSION
Viral expression systems are not only useful in gene transfer
experiments, but also in heterologous protein production. In most
cases, structural or regulatory elements of animal and human
viruses represent the key elements in these systems, restricting their
Figure 5. Chimeric Gag/K28a particles displaying the toxic a-subunit
of the K28 virus toxin assemble into yeast VLPs that induce an in vivo
antibody response in rabbit. (A) SDS-PAGE and Coomassie-Blue
staining of recombinant Gag/K28a particles expressed and assembled
in yeast and purified by sucrose gradient centrifugation. (B) Western
analysis of the a/b heterodimeric K28 virus toxin probed with a rabbit
polyclonal antiserum raised against chimeric Gag/K28a VLPs assembled
in yeast. Positions of the heterodimeric K28 toxin (a/b) and its
tetrameric derivative [a/b]2 that forms spontaneously under conditions
of a non-reducing SDS-PAGE are indicated (PI, pre-immune serum).
doi:10.1371/journal.pone.0000415.g005
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PLoS ONE | www.plosone.org 6 May 2007 | Issue 5 | e415Figure 6. GFP expression and purification via recombinant yeast VLPs. (A) schematic outline of a Gag/GFP fusion (GTXG) for in vivo VLP assembly
and purification of the model protein GFP. The particular function of each domain within the protein fusion is indicated. (B) SDS-PAGE and anti-GFP
western analysis of recombinant GTXG particles assembled in yeast and purified by sucrose gradient centrifugation. (C) Release of GFP from GTXG
particles by factor Xa cleavage [rGFP, recombinant GFP; M, full range rainbow marker, Amersham]. (D) Single-step purification of GFP obtained after
factor Xa treatment and ammonium sulfate (AS) precipitation (S, supernatant; P, pellet) by hydrophobic interaction chromatography on a HIC column.
Samples were separated by SDS-PAGE and probed with anti-GFP and/or anti-T7. (E) Coomassie-Blue staining of pooled GFP-containing HIC fractions
after Amicon ultrafiltration through a 10 kDa cut-off membrane [rGFP, recombinant GFP; M, full range rainbow marker, Amersham].
doi:10.1371/journal.pone.0000415.g006
Yeast VLP Carrier System
PLoS ONE | www.plosone.org 7 May 2007 | Issue 5 | e415Figure 7. Chimeric yeast VLPs expressing bacterial esterase (EstA) function as recyclable bioreactor and show efficient substrate conversion. (A)
Electron micrograph of recombinant Gag/EstA particles prepared from yeast were purified by sucrose gradient centrifugation, negatively stained with
uranyl acetate/methyl cellulose and subsequently used for electron microscopy (magnification 340,000). (B) Linear correlation between the 4-
nitrophenol concentration of up to 1 mM and its absorption at 405 nm. (C) Kinetics of Gag/EstA-driven hydrolysis of 4-nitrophenylacetate (280 mM)
to 4-nitrophenol and acetate at 25uC in PBS50 buffer (pH 7.0). (D) Coomassie-Blue staining and western analysis of Gag/EstA particles before and after
cata-lysis and recycling by ultracentrifugation. BSA (1 and 3 mg) was used as loading control [M, full range rainbow marker, Amersham]. (E) Specific
activity of chimeric Gag/EstA particles before and after recycling.
doi:10.1371/journal.pone.0000415.g007
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we engineered the yeast totivirus L-A and demonstrated its
feasibility for being used as unique expression system in a lower
eukaryotic host. The potential of its capsid as platform for the
presentation of immunogens was demonstrated by using the
HCMV tegument protein pp65 as model antigen. This structural
protein represents the major target of cellular immune response
during HCMV infection [20,21], and also in vitro HCMV-infected
cells are recognized by 70–90% of cytotoxic T lymphocytes
(CTLs) [22]. Besides inducing a strong CD8
+ T cell response,
pp65 can also activate CD4
+ T cells [23] making it an ideal
candidate in developing an HCMV vaccine ensuring both,
humoral and cellular immunity.
To analyze recombinant yeast VLPs for their potential as non-
replicating particle vaccine, we fused an N-terminally truncated
pp65 variant (Dpp65) of HCMV containing immunodominant T
cell epitopes to the C-terminus of Gag and showed that it self-
assembled into VLP chimeras when expressed in the yeast cell
cytosol. Electron microscopy revealed a spheric symmetry of the
recombinant particles (Gag/Dpp65) in which the Dpp65 moiety
was buried inside the capsid, analogous to Pol in the natural L-A
virus [11]. The ‘‘in viro’’ localization of Dpp65 either inside or
outside the particle was judged in two ways: (i) by immunogold
labelling and electron microscopy, and (ii) by analyzing co-
sedimentation profiles of Gag/Dpp65 and monoclonal anti-pp65
in a sucrose density gradient (Powilleit and Schmitt, unpublished).
In contrast to non-modified (naked) Dpp65 which was only weakly
expressed and subject to proteolytic degradation in vivo, particle-
associated Dpp65 was highly stable and effectively protected
against the action of host cell proteases. In an ex vivo stimulation
assay in which memory T cell stimulation can be quantified and
characterized in human whole blood [14], purified Gag/Dpp65
particles - in contrast to non-modified Gag - resulted in a significant
activation of CD8
+ T lymphocytes, while frequencies of activated
CD4
+ helper T lymphocytes (HTLs) were generally low. The same
holds true for chimeric VLPs in which the Dpp65 moiety was
exposed at the outer VLP surface by insertion into surface-exposed
loops of Gag immediately N-terminal to position S182 and flanked
by flexible spacer elements (Powilleit and Schmitt, unpublished). In
all cases the observed bias in activation of CD8
+ Tl y m p h o c y t e sb y
exogenous antigen points to an alternative presentation pathway
favouring association of pp65 epitopes with MHC I. In the classical
pathway of antigen presentation, peptides derived from exogenous
proteins or particles are exposed in complex with MHC II molecules
on the cell surface where interaction with complementary T cell
receptors leads to an activation of CD4
+ HTLs. This mechanism is
apparently true for the positive control antigen used in this study,
a lysate of HCMV-infected fibroblasts containing both soluble as
well as virion-associated pp65. In one out of four blood samples,
Gag/Dpp65 also induced a CD4 T cell response, indicating that
Dpp65 peptidescanalsobepresentedincomplexwith MHCII.Due
to the N-terminal truncation in Dpp65, HTL epitopes in pp65 such
as peptides 11, 71 and/or 72 are lacking [23], probably attenuating
its ability to induce a more frequent CD4
+ Tc e l lr e s p o n s e .
In contrast to MHC II, MHC I-associated presentation of
peptides is considered to be restricted to endogenously synthesized
proteins, initiating with proteasomal processing in the cytoplasm.
Upon targeting on the cell surface, the MHC I/peptide complex
can activate CD8
+ T cells through interaction with the
corresponding T cell receptor [24]. More recent studies have
indicated that proteins taken up by phagocytosis can also be
presented by MHC I molecules, thereby promoting CD8
+ CTL
proliferation [25]. Such alternative antigen presentation (also
known as cross-presentation) has been observed in phagocytic cells
upon engulfment of bacterial cells or viral particles [26–30]. Since
recombinant Gag/Dpp65-VLPs share the particulate nature with
these antigens, a cross-presentation pathway might also exists for
them as well as for pp65 associated to intact HCMV virions
(present in the positive control).
Current strategies in HCMV vaccine development imply the
application of live, attenuated virus strains, DNA vectors coding
for immunodominant HCMV proteins and/or genetically mod-
ified carrier viruses [31]. Although these approaches might be
well-tolerated and immunogenic, they bear the risk of reconverting
to original virulence, inducing anti-DNA antibodies or recombin-
ing with the host cell genome [32,33]. In addition, the production
of most of these vaccines in human cell lines is costly, time-
consuming and hardly suitable to an industrial scale-up [34]. In
contrast, yeast is regarded as safe due to its GRAS status and
widely accepted as a profitable host to produce biotechnologically
and pharmaceutically relevant proteins [35]. As proof of principle
for a yeast vaccine based on recombinant VLP chimeras, we
intend to use Gag/Dpp65 particles and HLA transgenic mice in
a murine HCMV model to analyze in vivo immune responses and
to evaluate vaccine potential of chimeric yeast VLPs.
Besides being attractive in vaccine development, the yeast viral
expression system described here is also interesting in foreign
protein production. This was demonstrated for a gene fusion in
which the 39-end of gag was sequentially extended by a T7 epitope,
a factor Xa cleavage site, and the coding sequence of GFP as
model protein. After in vivo expression, the protein fusion self-
assembled into hybrid yeast VLPs from which GFP could be
entirely released from its Gag carrier by factor Xa cleavage. Single-
step purification via hydrophobic-interaction chromatography and
subsequent ultrafiltration resulted in a highly pure GFP prepara-
tion with an overall yield of 0.2 mg purified and biologically active
GFP from 1 liter yeast culture (and a density of 5610
8 cells/ml).
The overall yield in heterologous GFP production via chimeric
yeast VLP expression falls within the broad-range levels of GFP
fusion protein production which has been shown to range over 3
orders of magnitude, from 4 mg/liter to 4 mg/liter yeast cell
culture [36,37]. Furthermore and in contrast to expression systems
based on yeast Ty retrotransposons exposing foreign proteins at
the outer VLP surface [38,39], recombinant Gag particles
described here contain their cargo within the inner capsid,
thereby effectively preventing proteolytic degradation. Especially
for the production of short-lived and unstable proteins (such as
pp65 from HCMV), the L-A-derived expression system might be
superior as it efficiently protects its cargo from proteolytic
degradation in the host cell cytosol. Furthermore, by using the
a-subunit of K28 toxin - which is cytotoxic when expressed in
yeast [16] - we could demonstrate that recombinant Gag-VLPs are
also suitable for the in vivo expression of a protein which is per se
toxic. In addition, Gag was also shown to be effective in the
expression of a particle-associated and recyclable biotechnical
enzyme, carboxylesterase A from B. gladioli [18]. Gag/EstA
protein fusions expressed in yeast assembled into VLP chimeras
that were catalytically active and effectively converted 4-
nitrophenylacetate into 4-nitrophenol and acetate. A hallmark of
this VLP-based ‘‘bioreactor’’ is its reusability in multiple substrate
conversions without loss in enzyme activity and its overall yield in
particle-associated specific esterase activity, being significantly
higher than esterase activity after cell surface display in E. coli or S.
cerevisiae [18,19]. In sum, these data demonstrate the efficiency of
the yeast L-A viral expression system in the production and
purification of recombinant proteins/enzymes in a particle-
associated manner, providing substantial yields of a functional
protein in sufficient quality without the need of time-consuming
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low-cost media makes S. cerevisiae and its chimeric Gag-VLPs
attractive for foreign protein production.
MATERIALS AND METHODS
Strains, oligonucleotides and plasmids
E.coli strainTOP10 [F
2 mcrA D(mrr-hsdRMS-mcrBC) W80lacZDM15
DlacX74 recA1 deoR araD139 D(ara-leu)7697 galU galK rpsL( S t r
R)
endA1 nupG] (Invitrogen) used for plasmid propagation was grown at
37uC in Luria Broth supplemented with 100 mg/ml ampicillin. All
plasmids and oligonucleotide primers used in this study are listed in
supplementary Table S1 and Table S2, respectively. Target gene
amplification was performed using High-Fidelity Taq polymerase
(Roche) according to the manufacturer’s instructions. PCR products
were subcloned into pCRHII-TOPO (Invitrogen) and checked by
DNA sequencing using primers M13for and/or M13rev (59-labeled
with infra-red dye 800; MWG). For Dpp65 amplification, template
JW4303 and primers 59pp65epi+39CMVepi were used. To obtain
plasmid pPGK-Dpp65, the Dpp65 fragment was inserted into pPGK
via EcoRI/BamHI. The gag-ORF, amplified using pTIL05 [40] as
template and primers 59L-A ORF1+39L-A ORF1, was cloned as
HindIII/BamHI fragment into vector pPGK to give pG. To obtain
expression plasmids pGAG/Dpp65 and pGTXG, PCR reactions
were carried out using the template/primer combinations JW4303/
59CMVepi+39CMVepi and pUG36/59T7Xa-GFP+39GFP, respec-
tively. Upon subcloning, both fragments were inserted as SacI/
BamHI fragment into pG. Plasmid yGTXG was constructed by
introducing the HindIII/BamHI GTXG fragment from pGTXG
into YEp352. The Xa gene (encoding the a-subunit of killer toxin
K28) was amplified using vector pM28-SL [16] as template and
primers 59SpeXal/39altaaBgl. Subsequently, the 59-terminal Spe I/
BamHIfragmentwasintegratedintoyGTXG[SpeI/BamHI]togive
yGTXaD.G T X aD [Hin dIII/Bam HI] was then inserted into
pPGK, and the GTXa fusion was completed by inserting the 39-
terminal Bgl II/Bam HI fragment of Xa into the Bam HI digested
vector pGTXaD. For amplification of the Ce fragment, template
JW4303 and primers 59pp65epi+39CMVepi were used. To obtain
plasmid pCe, the Ce fragment was inserted into pPGK via Eco RI/
Bam HI. The multiple protease-deficient S. cerevisiae strain S86c
[MATa ura3-2 his3 pra1 prb2 prc1 cps1 L-0 M-0] represents a heat-
cured, virus-free derivative of strain S86 [41] that was employed for
the in vivo assembly of hybrid VLPs as well as for the expression of
soluble (naked) Dpp65 in the yeast cell cytosol. If not otherwise
stated, cells were cultivated in YPD at 30uC. Yeast cells were
transformed by the lithium acetate method [42] and transformants
were selected on synthetic complete medium lacking uracil (Ura-d/
o). Since in a yeast super-killer ski3 mutant (defective in exosome
complex components) translation efficacy of the poly(A)
2 transcript
of L-A is more effective and dsRNA copy number is significantly
increased [43,44], a Dski3 variant of strain BY4741 [MATah i s 3 D1
leu2D0 met15D0 ura3D0 Dski3] (Euroscarf) was used to prepare
natural L-A virions.
VLP preparation
Transformants of the indicated yeast strain were incubated in
400 ml Ura-d/o at 220 rpm (30uC, in a 1 l-Erlenmeyer flask) to
a density of 5610
7–5610
8 cells/ml, harvested by 10 min
centrifugation at 5,0006g( 4 uC), washed in prechilled H2O,
thereafter in 1 M sorbitol, and finally resuspended in 50 ml cold
PBSES (150 mM NaCl, 10 mM Na2HPO4 pH 7.4, 10 mM
EDTA, 1 M sorbitol). Subsequently, 2-mercaptoethanol (1:2,000)
and 2.5 mg zymolyase 20T (Seikagaku, Japan) were added. Upon
1.5 h incubation at 120 rpm (30uC), spheroplasts were collected
by 15 min centrifugation at 5006g( 4 uC) and washed in cold
PBSES. Thereafter, cells were resuspended in 10 ml PBSE
(150 mM NaCl, 10 mM Na2HPO4 pH 7.4, 10 mM EDTA) and
disrupted by vortexing seven times for 1 min (with 1 min breaks in
between to cool samples on ice) in the presence of 12 g glass beads
(0.45–0.55 mm in diameter). The resulting raw extracts were
supplemented with 10 ml PBSE and centrifuged at 10,0006g for
1h( 4 uC) to sediment glass beads and cell debris. The supernatant
was adjusted with PBSE to 23 ml and then layered onto a cushion
of 15 ml 45% sucrose. During ultracentrifugation at 69,2606g
overnight (4uC; Beckman SW28 rotor) only structures of high
molecular weight pass the cushion and form a pellet. Sub-
sequently, the cushion pellet was resuspended in 1 ml PBSE and
layered onto a linear density gradient (38 ml) of 20–70% sucrose.
Upon further ultracentrifugation at 76,7406g overnight (4uC) the
gradient was fractionated into 18–20 fractions (each 2 ml) while
the gradient pellet was resuspended in 2 ml PBSE. Aliquots of
each fraction were subjected to SDS-PAGE followed by western
analysis or Coomassie blue staining. For reisolation of recombi-
nant VLPs, a maximum of 12 fusion protein containing gradient
fractions was pooled, supplemented with PBSE to 38 ml, and
again ultracentrifuged at 76,7406g overnight (4uC). Finally, the
VLP pellet was resuspended in 100–500 ml PBSE. The procedure
described above was also used to prepare natural L-A particles
from yeast strain BY4741 starting from a 200 ml YPD culture
grown to a density of 5610
8 cells/ml.
Rapid extraction (S80 method) and detection of
intracellular proteins
Yeast cells from a 1 ml overnight culture were collected by 3 min
centrifugation at 8,5006g (20uC) and washed in H2O. Upon
removal of the supernatant, the pellet was resuspended in the
residual liquid and incubated at 280uC for 15 min. Cells were
thawed on ice, mixed with 100 ml3 6TT sample buffer (0.15 M
Tris/HCl pH 6.8, 12% SDS, 30% glycerol, 0.03% Coomassie Blue
R250, 0.6% 2-mercaptoethanol) and heated at 100uC for 5–10 min
with occasional vortexing. Thereafter, samples were centrifuged at
17,0006g for 3 min (20uC) to pellet cell debris. Subsequently, the
supernatant was transferred into a fresh reaction tube, and 5–20 ml
aliquots were separated by SDS-PAGE. Aliquots of the gradient
fractions and the cushion and VLP pellets, as well as HIC fractions
(20 ml each) were mixed with 10 ml3 6TT sample buffer, boiled for
3 min and subjected to SDS-PAGE. Protein samples were applied
onto 7.5% SDS-polyacrylamide gels and run in Tris/Tricine buffer
[45]. Upon separation, proteins were either stained with Coomassie
Brilliant Blue R250 (Roth) or blotted onto polyvinyl difluoride
membranes [46]. Blots were probed with monoclonal anti-pp65
(Novocastra), anti-T7 (Novagen), anti-GFP (Roche) or polyclonal
antibodies raised in rabbit against native Gag-VLPs (anti-Gag) or
chimeric Gag/K28a particles (anti-Gag/K28a) followed by treat-
ment with an alkaline phosphatase-coupled secondary anti-mouse
immunoglobulin (Sigma). For colorimetric signal detection blots
were covered with NBT/BCIP solution (Roche) according to the
instructions of the manufacturer. Protein concentration was
determined by using a bicinchoninic acid assay kit (Sigma).
Alternatively, defined amounts of bovine serum albumin (BSA;
Sigma) served as standard for semi-quantitative determination of
protein concentration after SDS-PAGE and Coomassie Blue
staining.
Transmission electron microscopy
An aliquot of gradient-purified VLPs was layered onto a cupper
grid (mesh 300–400; coated with poly-L-lysine) and allowed to
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with 30 ml TBS (150 mM NaCl, 100 mM Tris/HCl pH 7.5) the
grid was incubated in uranyl acetate/methyl cellulose (1.8%/
0.2%) for 5 min at room temperature (negative staining) before it
was slowly dried. For analysis and documentation of VLP samples,
a transmission electron microscope type TECNAI G
2 (FEI)
equipped with a MegaView III camera (Olympus) was used.
Protein processing using factor Xa and hydrophobic
interaction chromatography (HIC)
To release the GFP moiety from chimeric particles, GTXG-VLPs
were prepared from gradient fractions and resuspended in 0.9 ml
H2O. Upon addition of Triton X-100 (1% final concentration) the
sample was rotated overnight at 20uC. Digestion was carried out
using 55 mU factor Xa/mg GTXG protein in a total volume of
4.5 ml at 20uC under rotation for 4 d. To remove residual intact
capsid and factor Xa, the sample was ultracentrifuged at 102,0006g
(4uC) for 1 h, and the supernatant was treated with Xarrest agarose
(Novagen) according to the manufacturer’s instructions. The
resulting sample (10 ml) was carefully supplemented with 850 mM
ammonium sulfate and subsequently centrifuged at 12,4006g( 4 uC)
for 1 h. The pellet was resuspended in 10 ml H2O while 2.5 ml
aliquots of the supernatant were applied onto a column of Phenyl
Superose HR5/5 (2 ml; Amersham Pharmacia) equilibrated in HIC
buffer (pH 7.4) containing 850 mM ammonium sulfate and
100 mM KH2PO4. The column was washed with the same buffer
and bound proteinswereelutedina lineargradient (15 ml) from850
to 51 mM ammonium sulfate/100 mM KH2PO4 (pH 7.4). The
column was run at 0.5 ml/min, and 1 ml fractions were collected
and analyzed by SDS-PAGE.
Microtiter activity assay
Catalytic activity in esterase-coupled VLPs was determined in
microtiter plates (96 flat-bottom wells; Nunc) using an MF reader
V2.9-0 (EMS). A stock solution of 80 mM 4-nitrophenylacetate
(dissolved in dimethyl sulfoxide) was diluted to the indicated
concentrations to serve as substrate solution. To start the reaction,
recombinant protein (5 ml) was added to 90 ml PBS50 buffer
(150 mM NaCl, 50 mM Na2HPO4, pH 7.0), finally completed
with 5 ml substrate solution to give a total volume of 100 ml. The
release of 4-nitrophenol was photometrically measured at 405 nm
(25uC) in 30 s intervals. Immediately prior to each measurement,
the samples were automatically shaken at 600 rpm. The absolute
activity [U] of the enzyme was calculated by the ratio of released
4-nitrophenol [mmol] within 1 min, while the specific activity is
given by the quotient of absolute activity to the protein amount
[U/mg].
Whole blood assay and flow cytometry
The procedures were performed as breviously described [15].
Briefly, T cell stimulations were carried out using heparinized
human blood (450 ml) of four HCMV-seropositive and one
HCMV-seronegative European individuals and different amounts
of antigen in a standard volume of 45 ml (adjusted with PBSE
buffer). Lysates of HCMV-infected and non-infected fibroblasts
(CMV-Ag and control-Ag, BioWhittaker) served as controls. To
determine the frequency of antigen-specific T cells by flow
cytometry, at least 25,000 cells - each of CD4
+ and CD8
+
lymphocytes - were analyzed on a FACScan (Becton Dickinson)
using the Cellquest software. CD4
+ and CD8
+ T cells were
identified by gating on the lymphocyte population via cell size and
granularity and their high CD4 or CD8 expression level,
respectively. Specifically activated T lymphocytes were identified
and quantified as CD69 and IFNc double-positive cells. Due to the
observation that negative controls can lead to a minimal activation
of T cells [15], the threshold of a significant response was defined
to be 0.05% of counted T lymphocytes.
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